R
R T D Oliver
Researcher at St Bartholomew's Hospital
Publications - 26
Citations - 885
R T D Oliver is an academic researcher from St Bartholomew's Hospital. The author has contributed to research in topics: Cancer & Etoposide. The author has an hindex of 14, co-authored 25 publications receiving 864 citations.
Papers
More filters
Journal Article
Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial
A. Ritchie,Gareth Griffiths,M K B Parmar,Sophie D. Fosså,Peter Selby,MA Cornbleet,G Sibley,Graham M. Mead,Stan B. Kaye,Owen,R T D Oliver,Pete Smith,P Whelan,P. A. Cook,Peter Fayers,P. A. Cook,J Webb,John Whitehead,A Lamont +18 more
TL;DR: The benefit of treatment with interferon-oc should be weighed against the drug's toxic effects and combined regimens of biological therapy and chemotherapy should now be compared with interferential monotherapy in randomised controlled trials.
Journal ArticleDOI
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Sophie D. Fosså,Sally P. Stenning,Arthur Gerl,Alan Horwich,Peter I Clark,Peter M Wilkinson,W. G. Jones,Marna Williams,R T D Oliver,Edward S. Newlands,Graham M. Mead,Michael Cullen,Stan B. Kaye,G. J. S. Rustin,P. A. Cook +14 more
TL;DR: Good prognosis parameters are: progression-free interval of > 2 years, CR to induction treatment and normal or low serum markers at relapse and the results of high-dose salvage chemotherapy should be interpreted on the background of these prognostic factors.
Journal ArticleDOI
A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma
Alan Horwich,R T D Oliver,Peter M Wilkinson,Graham M. Mead,S. J. Harland,Michael Cullen,J. T. Roberts,Sophie D. Fosså,David P. Dearnaley,E. Lallemand,Sally P. Stenning +10 more
TL;DR: The limited size of this trial rendered it unable to exclude a 19% lower progression-free survival and survival in those treated with single agent carboplatin which would be important clinically, and the trial has not demonstrated statistically significant differences in the major survival endpoints.
Journal ArticleDOI
Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding.
TL;DR: CL56 has a low objective response rate in the management of absolute hormone refractory prostate cancer and re-induction of hormone sensitivity following failure of chemotherapy was an unexpected finding that requires further study.
Journal ArticleDOI
Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome.
Daniel M. Berney,Gabrielle Fisher,M. W. Kattan,R T D Oliver,Henrik Møller,Paul A. Fearn,James A. Eastham,Peter T. Scardino,Jack Cuzick,Victor E. Reuter,Christopher S. Foster +10 more
TL;DR: The aim is to assess the possible reasons for error in the diagnosis of prostatic cancer with available follow‐up data and to establish a methodology to investigate these reasons.